<ul><li>Dutch-based cellular technology company QurieGen has raised €2.2M in a pre-seed funding round, supported by investors including Tensor Ventures, Lighthouse Ventures, BSV Ventures, Moondust Ventures, and 22 Hor Invest, as well as Tim Draper of Draper Associates.</li><li>The funding will be used to develop AI-based technology to accelerate drug development progress in oncology and enhance the drug discovery and development process.</li><li>QurieGen's platform combines proprietary technology for cellular mapping, single-cell genomics, and advanced data science to build predictive disease biology and drug response models, reducing risks and accelerating drug discovery.</li><li>Selected for the prestigious NATO DIANA program, QurieGen will receive funding, access to test centers, and participation in dedicated accelerators to develop dual-use technologies applicable in both civilian and defense sectors.</li></ul>

Dutch-based QurieGen raises €2.2M to build ‘Google Maps for cells’ and transform cancer drug discovery

Discover more